Want to see SNWV full AI Analyst Report?
SNWV Stock Chart & Stats
$5.93
$0.17(2.87%)
At close: 4:00 PM EDT
$5.93
$0.17(2.87%)
Day’s Range― - ―
52-Week Range$5.27 - $46.59
Previous Close$6.1
Volume111.03K
Average Volume (3M)78.76K
Market Cap
$50.58M
Enterprise Value$97.34
Total Cash (Recent Filing)$9.38M
Total Debt (Recent Filing)$20.71M
Price to Earnings (P/E)3.4
Beta1.35
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding8,602,309
10 Day Avg. Volume75,518
30 Day Avg. Volume78,757
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)157.84
Price to Sales (P/S)5.80
P/FCF Ratio132.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$51.35M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthSustained growth in applicator and consumables revenue points to a transition toward higher‑frequency, recurring revenue streams that are more predictable and margin-accretive. Over 2–6 months this supports cash conversion, customer stickiness and a defensible revenue base versus one-time system sales.
Installed Base ExpansionA growing installed base increases addressable recurring revenue and reinforces clinical adoption. More installed systems drive replacement/applicator demand and create network effects with clinicians, creating a durable foundation for consumable sales and long-term customer relationships.
Improved Cash Generation & Lower DebtRecent positive operating and free cash flow combined with materially reduced debt improves financial flexibility and reduces refinancing risk. This enhances the firm's ability to fund R&D, sales initiatives and absorb reimbursement shocks, strengthening survival odds over the medium term.
Bears Say
Revenue VolatilityLarge and rapid top-line swings indicate demand unpredictability and make earnings and cashflow less reliable. Durable planning, hiring, and R&D allocation become harder; persistent volatility can erode margins and capital buffers if recurring revenue growth doesn’t fully offset capital sales declines.
Reimbursement/regulatory RiskPotential CMS reimbursement cuts materially affect clinicians' economics and could reduce procedure volumes or pricing power. Regulatory shifts of this magnitude can structurally depress demand for capital and consumables across quarters, altering long‑term adoption curves and revenue durability.
Fragile Capital StructureThin equity and elevated leverage leave the company sensitive to earnings or reimbursement shocks. Even with recent debt reduction, limited capital reserves constrain strategic optionality and increase bankruptcy or dilution risk if cash generation weakens over the next several quarters.
Sanuwave Health News
SNWV FAQ
What was Sanuwave Health’s price range in the past 12 months?
Sanuwave Health lowest stock price was $5.27 and its highest was $46.59 in the past 12 months.
What is Sanuwave Health’s market cap?
Sanuwave Health’s market cap is $50.58M.
When is Sanuwave Health’s upcoming earnings report date?
Sanuwave Health’s upcoming earnings report date is Nov 06, 2026 which is in 87 days.
How were Sanuwave Health’s earnings last quarter?
Sanuwave Health released its earnings results on Aug 06, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Sanuwave Health overvalued?
According to Wall Street analysts Sanuwave Health’s price is currently Overvalued.
Does Sanuwave Health pay dividends?
Sanuwave Health does not currently pay dividends.
What is Sanuwave Health’s EPS estimate?
Sanuwave Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sanuwave Health have?
Sanuwave Health has 8,602,309 shares outstanding.
What happened to Sanuwave Health’s price movement after its last earnings report?
Sanuwave Health reported an EPS of -$0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2%.
Which hedge fund is a major shareholder of Sanuwave Health?
Currently, no hedge funds are holding shares in SNWV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanuwave Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
SNWV Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.23%
Trailing 12-Months
Company Description
Sanuwave Health
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. The company was founded on May 6, 2004 and is headquartered in Eden Prairie, MN.
SNWV Company Deck
SNWV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong execution on the recurring applicator/consumables business with record unit volumes, positive adjusted EBITDA and a solid liquidity position, contrasted with severe near-term headwinds in system sales driven by used-system cannibalization and industry disruption from CMS reimbursement changes. Management is responding by diversifying into stickier hospital and other indications and investing in R&D, but it has withdrawn guidance due to regulatory uncertainty. Highlights around recurring revenue growth and balance sheet health are meaningful, but the magnitude of the capital-sales decline, reimbursement risk, and the guidance withdrawal temper near-term outlook.View all SNWV earnings summariesTechnical Analysis
Cerus
―
Senseonics Holdings
―
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Ownership Overview
21.98% Insiders
7.43% Mutual Funds
0.45% Other Institutional Investors
65.76% Public Companies and
Individual Investors